Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and Erlotinib in NSCLC Progressing on Erlotinib
NCT00750698Phase 2Terminated
- Sponsor
- Syndax Pharmaceuticals
- Start
- Aug 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in non-small cell lung carcinoma (NSCLC), sponsored by Syndax Pharmaceuticals. Started Aug 2008; status: terminated.
02
Drugs
entinostat
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00750698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750698.